Developing next generation treatments to preserve vision for patients with diseases affecting the back of the eye

Company, THR-149, THR-687 - Press Releases archive

7 May 2020
Oxurion NV Business Update - Q1 2020
19 Dec 2019
Oxurion NV to Focus Clinical Development on Molecules Targeting VEGF Independent Pathways for Treatment of DME
9 Sep 2019
Oxurion NV Reports Additional Positive Topline Data from Phase 1 with THR-149, a novel, potent plasma kallikrein inhibitor for DME
2 Sep 2019
Oxurion to make a late-breaker presentation of topline THR-149 (Plasma Kallikrein inhibitor) Phase 1 clinical data at EURETINA 2019
1 Jul 2019
Oxurion NV Reports Positive Topline Phase 1 Results with THR-149, a novel, potent plasma kallikrein inhibitor for the treatment of DME
24 Apr 2019
Oxurion NV announces full enrollment in Phase 1 trial evaluating the safety of plasma kallikrein inhibitor THR-149 for treatment of DME, ahead of schedule
28 Feb 2019
Oxurion NV to Present Preclinical Evaluation of Plasma Kallikrein Inhibition for DME at 2019 EURETINA Winter Meeting
25 May 2018
ThromboGenics Enrolls First Patient in Phase 1 Clinical Study Evaluating THR-149, a plasma kallikrein inhibitor, for treatment of Diabetic Macular Edema (DME)
23 May 2018
ThromboGenics to present a preclinical overview of its two most advanced diabetic eye disease clinical candidates, THR-317 and THR-149, at EASDec 2018
6 Apr 2018
ThromboGenics announces publication in The Journal of Medicinal Chemistry of preclinical data supporting therapeutic potential of THR-149
20 Apr 2017
ThromboGenics Achieves Important Milestone in the Development of THR-149, A Novel Plasma Kallikrein Inhibitor for Diabetic Macular Edema